ClinicalTrials.gg
Status unknownNCT01012349Updated Jan 28, 2011

Efficacy and Safety Clinical Trial of the Combination of Acetylsalicylic Acid, Sodium Bicarbonate and Citric Acid, Produced by Geolab Pharmaceutical Industries Ltd., Compared to Acetylsalicylic Acid (Aspirin ® - Bayer) in Patients With Episodic Tension-type Headache.

A Phase 2/3 interventional study of Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965) and Aspirin - Bayer in Treatment of Episodic Tension Headache, sponsored by Azidus Brasil. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-28.

Sponsored by Azidus Brasil · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2010), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims is to evaluate, two hours after a single administration, the rate of sustained response produced by the association Geolab consisting of acetylsalicylic acid, sodium bicarbonate and anhydrous citric acid - oral powder, with the active comparator acetylsalicylic acid (Aspirin ® -- Bayer) - a simple tablet for the treatment of acute pain in patients with mild to moderate CTTE, using for both the visual analog scale pain - VAS.

Read the detailed description

The secondary objectives of the study are to evaluate:

  • Modification of gastric pH after administration of drugs by measuring with gastroesophageal pH Monitor, comparing the results between the groups;
  • The incidence of administration of rescue medications, through the accounts of patients and researchers, comparing the results between the groups;
  • The percentage of improvement in time 30, 60, 90 and 120 minutes after administration, using the visual analog scale (VAS), comparing the results between the groups;
  • Evaluate the gastric symptoms before and after treatment by clinical investigation of patients, comparing the results between the groups;
  • Evaluate the change in associated symptoms (photophobia, phonophobia, nausea, vomiting), using 4-point scale (0 - absent 1 - mild 2 - moderate 3 - severe), comparing the results between the groups;
  • Assess the quantitative and qualitative parameters related to adverse reactions, comparing the results between the groups.
02

Conditions studied

  • Treatment of Episodic Tension Headache

Browse trials for

03

In context

Tension-Type Headache

143 studies on the registry are indexed under Tension-Type Headache; 42 are open to participants now.

This study's planned enrollment of 152 is above the median of 60 across 108 interventional studies indexed under Tension-Type Headache.

Browse Tension-Type Headache studies →

Lead sponsor

Azidus Brasil is the lead sponsor of 80 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agreed to participate in the study expressed by signing the two copies of the and informed consent (IC) after approved by the IRB;
  • Minimum age of 18 years;
  • Clinical history of TTH, according to the criteria of the International Classification of Headache of the International Headache Society, in face of crisis.

Exclusion criteria

Exclusion Criteria:

  • Headache, migraine
  • Chronic Tension-Type Headache (CTTH)
  • Altered mental status
  • Vital signs changed
  • established or suspected pregnancy and lactation
  • History of allergy to components of study drugs
  • Current treatment with methotrexate
  • Current treatment with Antinauseants
  • Current treatment with anticoagulants such as heparin or coumarin-derivative
  • gastric or duodenal disorders, chronic or recurrent active
  • Liver and kidney disease severe
  • Use of medications that have drug interactions with AAS
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Test

    Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)

    Drug: Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)

  • Active comparator
    Comparator

    Acetylsalicylic acid - (Aspirin - Bayer)

    Drug: Aspirin - Bayer

Interventions

  • DrugAssociation: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)

    Drug pages: Aspirin · Sodium Bicarbonate · Citric Acid

    1 tablet in an episody of headache

  • DrugAspirin - Bayer

    1 tablet in an episody of headache (Aspirin 500mg)

06

What researchers measure

Primary outcomes

  1. The primary efficacy endpoint is the rate of sustained response (percentage of subjects who have no pain) two hours after the drug administration.

    Time frame: 0, 30, 60, 90 and 120 minutes

Secondary outcomes

  1. • Reduction of associated symptoms (photophobia, phonophobia, nausea, vomiting); • Symptoms stomach before and after treatment • Change in gastric pH after administration; • Incidence of administration of rescue medications; • Change in pain

    Time frame: 30, 60, 90 and 120 minutes after administration

07

Study locations

1 site
  • Lal Clinica Pesquisa E Desenvolvimento Ltda
    Valinhos, SP 13270000, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of May 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2009
First posted
Nov 13, 2009
Start
Feb 2011
Primary completionEst.
May 2011
CompletionEst.
Aug 2011
Last update
Jan 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01012349
Lead sponsor
Azidus Brasil
First posted
Nov 13, 2009
Start date
Feb 2011
Primary completion
May 2011 (estimated)
Completion
Aug 2011 (estimated)
Last update
Jan 28, 2011

Study contacts

alexandre Frederico, physician
Contact
dr.alexandre@alclinica.com.br
55 19 3829-3822

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Sodium Bicarbonate · Citric Acid

Start the discussion